A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.

Obesity increases the risk of numerous secondary diseases such as type 2 diabetes, high blood pressure and mental illness. Prof. Dr. Kerstin Stemmer, Professor of Molecular Cell Biology at the ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

In fact, you may have gotten more than a few targeted ads on social media from telehealth platforms selling these cheaper GLP ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide ...